PET scans to better understand multiple myeloma risk and disease
Part of Blood & lymphatic, Cancer clinical trials.
This study uses a special imaging test called a PET scan to learn more about multiple myeloma and how it responds to treatment. The results may help doctors better predict outcomes and tailor care for people with newly diagnosed disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma and are scheduled to receive chemotherapy followed by a stem cell transplant.
- You are at least 18 years old.
- You have a PET scan that shows active myeloma before or within 7 days of starting treatment.
- You are generally able to care for yourself (WHO performance status 0-2) or have a higher score only due to myeloma itself.
- You do not have uncontrolled diabetes or any other cancer that is not considered cured.
- You are not pregnant or breastfeeding and are willing to give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special PET/CT scan (using fluciclovine, a radioactive tracer) can more clearly see multiple myeloma in the body. It may help doctors evaluate the extent of the disease and guide treatment decisions.
This study compares a new investigational drug (AZD0120) with a standard stem cell transplant for people with newly diagnosed multiple myeloma who have already completed initial treatment. The goal is to see if the new drug works as well as or better than the transplant in keeping the cancer from coming back.
This trial compares two types of PET/CT scans to see which one better finds lesions (areas of disease) in people with newly diagnosed multiple myeloma. If you qualify, you may help doctors choose the most useful scan to guide care.
This study tests a new imaging method that uses a special tracer to find multiple myeloma cells in the body. It may help doctors see the disease more clearly and guide treatment.
This study tests a new imaging method (PET-enabled dual-energy CT) to see if it can better show how multiple myeloma responds to CAR T-cell therapy. It may help doctors personalize treatment and catch changes early.
This trial tests a new type of PET scan that uses a radioactive tracer (68Ga-BCMA) to find active multiple myeloma cells in your body. It may help doctors better detect and monitor the disease.
Hear when a new Newly Diagnosed Multiple Myeloma (NDMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.